Clinical Study on the Treatment of Mixed Component Cornea for High Risk Keratoplasty
Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University
About this trial
Last updated 4 years ago
Study ID
2020KYPJ111
Status
Unknown
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18 to 70 Years
All Sexes
Trial Timing
Ended 3 years ago
What is this trial about?
Because of the immunologically privileged nature of the cornea, the graft rejection rate is less than 10% for low-risk keratoplasty. But when the cornea performed 2 or more quadrants of corneal neovascularization after ocular trauma or infection, the graft rejection rate is more than 65%, it is called high-risk keratoplasty.
This study will observe the graft survival of high-risk corneal transplantation using mixed component cornea from different donors.
What are the participation requirements?
Inclusion Criteria
* Central corneal opacity involving full layer
* Corneal neovascularization in two or more quadrants
* Patients must be willing and able to return for scheduled follow-up examinations for 12 months after surgery
* Ages：18 -70 Years
Exclusion Criteria
* Central corneal opacity not involving the endothelial layer
* Less than two quadrants of corneal neovascularization
* History of Stevens-Johnson syndrome or Sjogren's syndrome
* Severe eyelid and conjunctival scar
* Loss of vision in contralateral eye
* Pregnant and lactating women